Brind.
  1. Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
  2. Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
  3. Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
  4. Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.

GLP-1 Drug Market Under Scrutiny Amid Sales Performance and Unregulated Sales Concerns

6 reports, 4 independent Updated Aug 9
Gone quiet
Reports
6
Developments
4
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Eli Lilly reported record sales for its GLP-1 drugs during the second quarter, with Mounjaro alone bringing in $9.9 billion in revenue, exceeding the FactSet estimate of $8.9 billion. The company's weight-loss injection, Zepbound, saw sales rise 46% in the quarter to $4.9 billion. Concurrently, a Premium Times investigation into the digital marketplace for Mounjaro found that vendors were selling the injections without requiring prescriptions and were downplaying side effects.

From premiumtimesng.com, morningstar.com

Why it matters

Some supportBrind's analysis of the reports

The GLP-1 market remains highly competitive between Eli Lilly and Novo Nordisk. The market's growth is being tested by both the successful sales performance of the drugs and the emergence of an unregulated digital sales channel for the products.

From premiumtimesng.com, morningstar.com

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Eli Lilly and CompanySpeculative

    The market for Eli Lilly's products could face increased regulatory pressure due to the identified unregulated sales channels.

How it developed

Newest first. Tap a step to see who reported it.
  1. The competitive GLP-1 market is facing scrutiny due to an investigation into unregulated drug market practices.1 source
  2. Analyst Trung Huynh reviewed Lilly's Q2 performance, while FactSet provided sales estimates amid competition.1 source
  3. Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.Sub-event
  4. Morgan Stanley forecasts GLP-1 market growth and notes Lilly's potential lead over Novo Nordisk.

Keep exploring

Part of

Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk. All 3 developments

Within Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.

The entities involved

Related events

Coverage

Newest first; wire copies grouped